Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue

Leah M. Wilson, Jessica Castle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Glycemic control is the mainstay of preventing diabetes complications at the expense of increased risk of hypoglycemia. Severe hypoglycemia negatively impacts the quality of life of patients with type 1 diabetes and can lead to morbidity and mortality. Currently available glucagon emergency kits are effective at treating hypoglycemia when correctly used, however use is complicated especially by untrained persons. Better formulations and devices for glucagon treatment of hypoglycemia are needed, specifically stable liquid glucagon. Out of the scope of this review, other potential uses of stable liquid glucagon include congenital hyperinsulinism, post–bariatric surgery hypoglycemia, and insulinoma induced hypoglycemia. In the 35 years since Food and Drug Administration (FDA) approval of the first liquid stable human recombinant insulin, we continue to wait for the glucagon counterpart. For mild hypoglycemia, a commercially available liquid stable glucagon would enable more widespread implementation of mini-dose glucagon use as well as glucagon in dual hormone closed-loop systems. This review focuses on the current and upcoming pharmaceutical uses of glucagon in the treatment of type 1 diabetes with an outlook on stable liquid glucagon preparations that will hopefully be available for use in patients in the near future.

Original languageEnglish (US)
JournalJournal of diabetes science and technology
DOIs
StateAccepted/In press - Feb 1 2018

Fingerprint

Glucagon
Hypoglycemia
Emergencies
Medical problems
Liquids
Insulin
Hormones
Type 1 Diabetes Mellitus
Closed loop systems
Drug products
Surgery
Congenital Hyperinsulinism
Drug Approval
Insulinoma
Diabetes Complications
United States Food and Drug Administration
Quality of Life
Morbidity
Equipment and Supplies
Mortality

Keywords

  • dual hormone artificial pancreas
  • glucagon
  • hypoglycemia
  • intranasal glucagon
  • mini-dose glucagon
  • type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Biomedical Engineering

Cite this

Stable Liquid Glucagon : Beyond Emergency Hypoglycemia Rescue. / Wilson, Leah M.; Castle, Jessica.

In: Journal of diabetes science and technology, 01.02.2018.

Research output: Contribution to journalArticle

@article{7bf6359dca3a4a20afee691564fe1eee,
title = "Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue",
abstract = "Glycemic control is the mainstay of preventing diabetes complications at the expense of increased risk of hypoglycemia. Severe hypoglycemia negatively impacts the quality of life of patients with type 1 diabetes and can lead to morbidity and mortality. Currently available glucagon emergency kits are effective at treating hypoglycemia when correctly used, however use is complicated especially by untrained persons. Better formulations and devices for glucagon treatment of hypoglycemia are needed, specifically stable liquid glucagon. Out of the scope of this review, other potential uses of stable liquid glucagon include congenital hyperinsulinism, post–bariatric surgery hypoglycemia, and insulinoma induced hypoglycemia. In the 35 years since Food and Drug Administration (FDA) approval of the first liquid stable human recombinant insulin, we continue to wait for the glucagon counterpart. For mild hypoglycemia, a commercially available liquid stable glucagon would enable more widespread implementation of mini-dose glucagon use as well as glucagon in dual hormone closed-loop systems. This review focuses on the current and upcoming pharmaceutical uses of glucagon in the treatment of type 1 diabetes with an outlook on stable liquid glucagon preparations that will hopefully be available for use in patients in the near future.",
keywords = "dual hormone artificial pancreas, glucagon, hypoglycemia, intranasal glucagon, mini-dose glucagon, type 1 diabetes",
author = "Wilson, {Leah M.} and Jessica Castle",
year = "2018",
month = "2",
day = "1",
doi = "10.1177/1932296818757795",
language = "English (US)",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",

}

TY - JOUR

T1 - Stable Liquid Glucagon

T2 - Beyond Emergency Hypoglycemia Rescue

AU - Wilson, Leah M.

AU - Castle, Jessica

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Glycemic control is the mainstay of preventing diabetes complications at the expense of increased risk of hypoglycemia. Severe hypoglycemia negatively impacts the quality of life of patients with type 1 diabetes and can lead to morbidity and mortality. Currently available glucagon emergency kits are effective at treating hypoglycemia when correctly used, however use is complicated especially by untrained persons. Better formulations and devices for glucagon treatment of hypoglycemia are needed, specifically stable liquid glucagon. Out of the scope of this review, other potential uses of stable liquid glucagon include congenital hyperinsulinism, post–bariatric surgery hypoglycemia, and insulinoma induced hypoglycemia. In the 35 years since Food and Drug Administration (FDA) approval of the first liquid stable human recombinant insulin, we continue to wait for the glucagon counterpart. For mild hypoglycemia, a commercially available liquid stable glucagon would enable more widespread implementation of mini-dose glucagon use as well as glucagon in dual hormone closed-loop systems. This review focuses on the current and upcoming pharmaceutical uses of glucagon in the treatment of type 1 diabetes with an outlook on stable liquid glucagon preparations that will hopefully be available for use in patients in the near future.

AB - Glycemic control is the mainstay of preventing diabetes complications at the expense of increased risk of hypoglycemia. Severe hypoglycemia negatively impacts the quality of life of patients with type 1 diabetes and can lead to morbidity and mortality. Currently available glucagon emergency kits are effective at treating hypoglycemia when correctly used, however use is complicated especially by untrained persons. Better formulations and devices for glucagon treatment of hypoglycemia are needed, specifically stable liquid glucagon. Out of the scope of this review, other potential uses of stable liquid glucagon include congenital hyperinsulinism, post–bariatric surgery hypoglycemia, and insulinoma induced hypoglycemia. In the 35 years since Food and Drug Administration (FDA) approval of the first liquid stable human recombinant insulin, we continue to wait for the glucagon counterpart. For mild hypoglycemia, a commercially available liquid stable glucagon would enable more widespread implementation of mini-dose glucagon use as well as glucagon in dual hormone closed-loop systems. This review focuses on the current and upcoming pharmaceutical uses of glucagon in the treatment of type 1 diabetes with an outlook on stable liquid glucagon preparations that will hopefully be available for use in patients in the near future.

KW - dual hormone artificial pancreas

KW - glucagon

KW - hypoglycemia

KW - intranasal glucagon

KW - mini-dose glucagon

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85042136039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042136039&partnerID=8YFLogxK

U2 - 10.1177/1932296818757795

DO - 10.1177/1932296818757795

M3 - Article

C2 - 29415555

AN - SCOPUS:85042136039

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

ER -